Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
CEMI's Cash to Debt is ranked higher than
96% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. CEMI: No Debt )
CEMI' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: No Debt

Equity to Asset 0.84
CEMI's Equity to Asset is ranked higher than
93% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. CEMI: 0.84 )
CEMI' s 10-Year Equity to Asset Range
Min: -2.07   Max: 0.86
Current: 0.84

-2.07
0.86
Interest Coverage No Debt
CEMI's Interest Coverage is ranked higher than
76% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.48 vs. CEMI: No Debt )
CEMI' s 10-Year Interest Coverage Range
Min: 28.82   Max: 9999.99
Current: No Debt

28.82
9999.99
F-Score: 2
Z-Score: 6.79
M-Score: -1.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -3.71
CEMI's Operating margin (%) is ranked higher than
69% of the 251 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.33 vs. CEMI: -3.71 )
CEMI' s 10-Year Operating margin (%) Range
Min: -302.06   Max: 15.41
Current: -3.71

-302.06
15.41
Net-margin (%) -3.18
CEMI's Net-margin (%) is ranked higher than
70% of the 251 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.44 vs. CEMI: -3.18 )
CEMI' s 10-Year Net-margin (%) Range
Min: -93.74   Max: 32.02
Current: -3.18

-93.74
32.02
ROE (%) -4.47
CEMI's ROE (%) is ranked higher than
68% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.21 vs. CEMI: -4.47 )
CEMI' s 10-Year ROE (%) Range
Min: -8840.71   Max: 67.84
Current: -4.47

-8840.71
67.84
ROA (%) -3.76
CEMI's ROA (%) is ranked higher than
70% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. CEMI: -3.76 )
CEMI' s 10-Year ROA (%) Range
Min: -53000   Max: 50.54
Current: -3.76

-53000
50.54
ROC (Joel Greenblatt) (%) -12.64
CEMI's ROC (Joel Greenblatt) (%) is ranked higher than
70% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. CEMI: -12.64 )
CEMI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3301.06   Max: 98.41
Current: -12.64

-3301.06
98.41
Revenue Growth (%) 18.10
CEMI's Revenue Growth (%) is ranked higher than
94% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. CEMI: 18.10 )
CEMI' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 26.4
Current: 18.1

0
26.4
EBITDA Growth (%) -19.00
CEMI's EBITDA Growth (%) is ranked higher than
61% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. CEMI: -19.00 )
CEMI' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 110.4
Current: -19

0
110.4
EPS Growth (%) -40.20
CEMI's EPS Growth (%) is ranked higher than
55% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. CEMI: -40.20 )
CEMI' s 10-Year EPS Growth (%) Range
Min: -67.1   Max: 72.9
Current: -40.2

-67.1
72.9
» CEMI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CEMI Guru Trades in

Q2 2012

CEMI Guru Trades in Q2 2012

John Keeley 15,000 sh (New)
» More
Q3 2012

CEMI Guru Trades in Q3 2012

John Keeley 15,000 sh (unchged)
» More
Q4 2012

CEMI Guru Trades in Q4 2012

John Keeley Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CEMI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Keeley 2012-12-31 Sold Out 0.0016%$4.05 - $5.26 $ 4.5-1%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.20
CEMI's P/B is ranked higher than
86% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. CEMI: 2.20 )
CEMI' s 10-Year P/B Range
Min: 0.11   Max: 3.3
Current: 2.2

0.11
3.3
P/S 1.50
CEMI's P/S is ranked higher than
87% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.11 vs. CEMI: 1.50 )
CEMI' s 10-Year P/S Range
Min: 0.02   Max: 1.88
Current: 1.5

0.02
1.88
EV-to-EBIT -36.93
CEMI's EV-to-EBIT is ranked higher than
53% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CEMI: -36.93 )
CEMI' s 10-Year EV-to-EBIT Range
Min: -36.3   Max: 172
Current: -36.93

-36.3
172
Shiller P/E 20.40
CEMI's Shiller P/E is ranked higher than
97% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CEMI: 20.40 )
CEMI' s 10-Year Shiller P/E Range
Min: 13.17   Max: 20.4
Current: 20.4

13.17
20.4
Current Ratio 4.45
CEMI's Current Ratio is ranked higher than
84% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. CEMI: 4.45 )
CEMI' s 10-Year Current Ratio Range
Min: 0.01   Max: 58
Current: 4.45

0.01
58
Quick Ratio 3.41
CEMI's Quick Ratio is ranked higher than
80% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. CEMI: 3.41 )
CEMI' s 10-Year Quick Ratio Range
Min: 0.01   Max: 58
Current: 3.41

0.01
58

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 5.40
CEMI's Price/Net Current Asset Value is ranked higher than
92% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CEMI: 5.40 )
CEMI' s 10-Year Price/Net Current Asset Value Range
Min: 0.36   Max: 9.88
Current: 5.4

0.36
9.88
Price/Tangible Book 2.20
CEMI's Price/Tangible Book is ranked higher than
91% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.28 vs. CEMI: 2.20 )
CEMI' s 10-Year Price/Tangible Book Range
Min: 0.16   Max: 2.94
Current: 2.2

0.16
2.94
Price/DCF (Projected) 4.30
CEMI's Price/DCF (Projected) is ranked higher than
82% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CEMI: 4.30 )
CEMI' s 10-Year Price/DCF (Projected) Range
Min: 1.49   Max: 5.81
Current: 4.3

1.49
5.81
Price/Median PS Value 8.50
CEMI's Price/Median PS Value is ranked higher than
60% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. CEMI: 8.50 )
CEMI' s 10-Year Price/Median PS Value Range
Min: 0.18   Max: 9.62
Current: 8.5

0.18
9.62
Earnings Yield (Greenblatt) -2.60
CEMI's Earnings Yield (Greenblatt) is ranked higher than
68% of the 248 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. CEMI: -2.60 )
CEMI' s 10-Year Earnings Yield (Greenblatt) Range
Min: -2.6   Max: 1762.7
Current: -2.6

-2.6
1762.7
Forward Rate of Return (Yacktman) -0.75
CEMI's Forward Rate of Return (Yacktman) is ranked higher than
66% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. CEMI: -0.75 )
CEMI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2967.8   Max: -0.9
Current: -0.75

-2967.8
-0.9

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, DGX, LIFE, ENZ, IDXX » details
Chembio Diagnostics, Inc. was formed in 1985. On May 5, 2004, the Company completed a merger with Chembio Diagnostic Systems Inc. through which Chembio Diagnostics Systems Inc. became the Company's wholly-owned subsidiary, and through which the management and business of Chembio Diagnostic Systems Inc. became its management and business. The Company with its subsidiaries develops, manufacture and market diagnostic tests that detect infectious diseases. The Company's main products presently commercially available are four rapid tests for the detection of HIV antibodies in whole blood, serum and plasma samples, all of which Employ lateral flow technology, and two of which were approved by the FDA in 2006. The Company's products are sold to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals and retail establishments both domestically and internationally. The Company's products are sold under its STAT PAK, SURE CHECK or DPP registered trademarks. The Company's HIV tests are qualitative (reactive/non-reactive) tests. Many of its competitors are substantially larger and have greater financial, research, manufacturing and marketing resources. The manufacturing and marketing of the Company's existing and proposed diagnostic products are regulated by the United States Food and Drug Administration ('FDA'), United States Department of Agriculture ('USDA'), certain state and local agencies, and/or comparable regulatory bodies in other countries.
» More Articles for CEMI

Headlines

Articles On GuruFocus.com
comment on CEMI Mar 06 2013 
comment on CEMI Mar 06 2013 

More From Other Websites
Chembio Signs Agreement With CDC Contractor to Develop a Multiplex Point-of-Care Test for Influenza... Nov 24 2014
8:51 am Chembio Diagnostics announced that it has entered into a follow-on, milestone-based... Nov 24 2014
Chembio Signs Agreement With CDC Contractor to Develop a Multiplex Point-of-Care Test for Influenza... Nov 24 2014
CHEMBIO DIAGNOSTICS, INC. Financials Nov 19 2014
CEMI: Record DPP Sales, CLIA Waiver Nov 07 2014
Chembio Diagnostics Reports Third Quarter 2014 Financial Results Nov 06 2014
Chembio Diagnostics Reports Third Quarter 2014 Financial Results Nov 06 2014
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Nov 06 2014
CHEMBIO DIAGNOSTICS, INC. Files SEC form 10-Q, Quarterly Report Nov 06 2014
Q3 2014 CHEMBIO DIAGNOSTICS, INC. Earnings Release - Before Market Open Nov 06 2014
Chembio to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, November... Nov 05 2014
Chembio to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, November... Nov 05 2014
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Nov 03 2014
Chembio's DPP(R) HIV 1/2 Assay Receives CLIA Waiver From FDA Oct 30 2014
Chembio's DPP(R) HIV 1/2 Assay Receives CLIA Waiver From FDA Oct 30 2014
CHEMBIO DIAGNOSTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Oct 28 2014
Shares Of Chembio Falling After Co. Fails To Provide Timeline On Product Deployment Oct 28 2014
Chembio Announces Agreements to Develop Point-of-Care Diagnostic Tests for Dengue Fever Virus and a... Oct 28 2014
Chembio Announces Agreements to Develop Point-of-Care Diagnostic Tests for Dengue Fever Virus and a... Oct 28 2014
Chembio Partners With Integrated BioTherapeutics, Inc. to Develop Point-of-Care Diagnostic Tests for... Oct 27 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK